

# Gil Awada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2171948/publications.pdf>

Version: 2024-02-01

24  
papers

429  
citations

1307366

7  
h-index

839398

18  
g-index

24  
all docs

24  
docs citations

24  
times ranked

617  
citing authors

#	ARTICLE	IF	CITATIONS
1	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 303.	1.8	89
2	Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2019, 2019, 1-17.	0.6	55
3	Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. , 2021, 9, e002296.		45
4	Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?. <i>European Journal of Endocrinology</i> , 2021, 184, K1-K5.	1.9	37
5	Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). , 2020, 8, e001146.		35
6	Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. <i>Supportive Care in Cancer</i> , 2020, 28, 3267-3278.	1.0	31
7	A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. <i>Cancers</i> , 2021, 13, 168.	1.7	24
8	Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	18
9	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , 2020, 8, 670.	2.1	17
10	Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report. <i>BMC Ophthalmology</i> , 2021, 21, 250.	0.6	9
11	A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. <i>Melanoma Research</i> , 2022, 32, 183-191.	0.6	9
12	Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse. <i>Cancers</i> , 2021, 13, 442.	1.7	7
13	A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). <i>Cancers</i> , 2021, 13, 2010.	1.7	7
14	A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2534-2534.	0.8	6
15	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	1.7	6
16	A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9585-9585.	0.8	5
17	Anti-PD-1: When to Stop Treatment. <i>Current Oncology Reports</i> , 2022, 24, 905-915.	1.8	5
18	Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1. <i>Case Reports in Oncology</i> , 2020, 13, 1031-1036.	0.3	4

#	ARTICLE	IF	CITATIONS
19	Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. <i>Current Oncology</i> , 2021, 28, 1630-1640.	0.9	4
20	Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights. <i>Current Opinion in Oncology</i> , 2022, 34, 115-122.	1.1	4
21	COVID-19 and Cushing's disease in a patient with ACTH-secreting pituitary carcinoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.2	4
22	A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2018, 29, x14.	0.6	3
23	Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab. <i>Annals of Oncology</i> , 2018, 29, x7.	0.6	3
24	Choriocapillaris Assessment In Patients Under Mek-Inhibitor Therapy For Cutaneous Melanoma: An Optical Coherence Tomography Angiography Study. <i>Seminars in Ophthalmology</i> , 2021, 36, 1-7.	0.8	2